Latest Content

  • The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

    The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

    Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief...

    Learn More
  • We need faster endpoints for targeted cancer drugs, and there is one

    We need faster endpoints for targeted cancer drugs, and there is one

    As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how targeted cancer drugs can benefit patients. He believes it can be created by combining two...

    Learn More
  • Six top tips to prepare for the new EU Clinical Trial Regulation

    Six top tips to prepare for the new EU Clinical Trial Regulation

    View Now

  • See Parexel's latest COVID-19 expert content

    View all
  • The impact of COVID-19 on clinical trials in rare disease and oncology

    The impact of COVID-19 on clinical trials in rare disease and oncology

    Learn More
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • Five competencies for operational excellence in cell and gene therapy clinical trials

    Five competencies for operational excellence in cell and gene therapy clinical trials

    View Now
  • Three ways to improve your chances that insurers will pay for a new CGT

    Three ways to improve your chances that insurers will pay for a new CGT

    When developing cell and gene therapies (CGTs), drug companies face significant hurdles. One of which is getting insurance companies to pay for these treatments that can potentially cure patients...

    Learn More
  • How market exclusivities can affect your development program

    How market exclusivities can affect your development program

    Learn More
  • 3 ways to reap the benefits of adaptive-trials

    3 ways to reap the benefits of adaptive-trials

    View Now
  • Parexel on the pulse2:08

    Parexel on the pulse

    Parexel regulatory expert, Mark Birse, gives an update on BREXIT.

    Watch Video
  • Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

    Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

    Learn More
  • The Evolving Cell and Gene Therapy (CGT) Sector in China

    The Evolving Cell and Gene Therapy (CGT) Sector in China

    Learn More
  • Virtual meetings are easy, right?

    Virtual meetings are easy, right?

    Recommendations for navigating the "new normal" and how to prepare for the future.

    Learn More
  • Parexel on the Pulse1:49

    Parexel on the Pulse

    Paul Bridges on the EU Clinical Trial Regulation (CTR)

    Watch Video
  • Five points to remember if FDA issues a Form 483

    Five points to remember if FDA issues a Form 483

    Learn More
  • Hong Kong Exchange: Nurturing China’s Biotech Valley

    Hong Kong Exchange: Nurturing China’s Biotech Valley

    About the Authors Daniel Huang is an Analyst based in the Hong Kong...

    Learn More
  • Crafting a genomics strategy early is key for successful oncology drug development

    Crafting a genomics strategy early is key for successful oncology drug development

    View Now
  • eBook: Biopharma in the COVID-19 World

    eBook: Biopharma in the COVID-19 World

    Learn More
  • NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

    NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

    Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...

    Learn More
  • Top 10 Myths About Working with the FDA for an Oncology Drug Approval

    Top 10 Myths About Working with the FDA for an Oncology Drug Approval

    Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and commercial success at the earliest stage. In that respect, regulatory considerations figure...

    Learn More
  • GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

    GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

    As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...

    Learn More
  • loading
    Loading More...